Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Foreign Exchange Impact on Consolidated Revenues YoY by Quarter
Foreign Exchange (FX) Impact on Consolidated Revenues YoY ($M) ($M)
Pfizer Foreign Exchange Impact on Consolidated Revenues YoY: $217M in Q2 2026, up 886.4% from a year earlier.
Where the Q2 2026 figure comes from
“Second-quarter 2026 revenues totaled $15.0 billion, an increase of $381 million, or 3%, compared to the prior-year quarter, reflecting an operational increase of $164 million, or 1%, and a favorable impact of foreign exchange of $217 million. The operational increase was driven by an increase in revenues for Eliquis, Padcev, the Vyndaqel family, Lorbrena and several other products across categories, partially offset by a decline in COVID-19 product revenues and several other products across categories. Excluding contributions from Comirnaty and Paxlovid, revenues for the second quarter grew 5% operationally. Additionally, second-quarter revenues of our Launched and Acquired Products (1) grew 18% operationally.”
Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Reported in Form 8-K Earnings Release.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Pfizer Foreign Exchange Impact on Consolidated Revenues YoY ($M), quarterly Q3 2020–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/fx-impact-rev
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.